The Flow Cytometry community recently lost our dear colleague,  Phil Marder who joined FloCyte just briefly in 2008. Phil died Saturday, January 30th, 2010 after his 14 month battle with brain cancer. He will be greatly missed!

 Phil received his graduate training in microbiology from The Ohio State University. Upon his graduation, he joined Eli Lilly research labs as an associate cell biologist. Early in his career, Phil was given the opportunity to introduce flow cytometry as an enabling technology for Lilly’s drug discovery platforms. In this hands-on role, Phil provided his company with the powerful flow applications of immunophenotypic analysis, calcium mobilization, DNA cell cycle detection and FACS^® cell sorting. During the late 1980’s, Phil began working with clinical development teams to incorporate flow cytometric technology into drug activity biomarker studies of early clinical trials. During the late 1990’s, Phil also helped introduce the breakthrough technology of multiplexed analyte detection (Luminex - xMAP^®) to Lilly. Phil’s vision of using flow cytometric analysis to uncover pharmacodynamic effects on the surrogate target cells in blood proved to be a boon for Lilly’s drug development processes. Over the ensuing years, Phil’s research leadership helped develop more than a dozen of these biomarkers assays for the clinic. More recently, he helped drive use of these assays in pre-clinical laboratory animal studies. Phil Marder rose through the ranks at Lilly to eventually lead a group of six investigators in his role as Research Advisor. During this time, he co-authored 48 peer-reviewed scientific articles and gave podium presentations at international conferences. He is internationally recognized for his leadership in applying flow cytometry technology to multiple stages of new drug development. These applications include optimization of cell lines for monoclonal antibody secretion, development of cell lines for neuroscience target screening, validation of primary cell assays for anti-inflammatory platforms, and most recently, detection of intracellular phosphoproteins for assaying kinase inhibitor activity of targeted cancer therapies. Phil retired from Lilly in 2007 after more than 30 years of outstanding accomplishments including two Lilly Presidential recognition awards. He has since begun a consulting career and incorporated Redram Consulting, LLC in order to use his extensive research experience for working with others in the Pharma/Biotech and Instrument/Reagent sectors for the purpose of helping them leverage flow cytometry technology for their own needs. 

Donations in memory of Phil can be made to the charity of Phil's choosing

http://www.voicesagainstbraincancer.org/